NCT02484716View on ClinicalTrials.gov

Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

January 29, 2018

Conditions
Telangiectasia, Hereditary HemorrhagicOsler Rendu Disease
Interventions
DRUG

Timolol nasal spray

Timolol 0.5% is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.

DRUG

Placebo nasal spray

Placebo (NaCl) is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.

Trial Locations (1)

69500

Hospices Civils de Lyon - Hôpital Femme Mère Enfant / Service de génétique Clinique, Bron

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT02484716 - Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO) | Biotech Hunter | Biotech Hunter